Home Archive
Archive
2023 Volume 44 Issue 9  Published: 2023-09-10
    Topic
  • Yeping YANG , Zhaoyun ZHANG
    doi: 10.13683/j.wph.2023.09.001

    Diabetic nephropathy (DN) is the main factor leading to end-stage renal disease, but the types and effects of current therapeutic drugs are limited. Mineralocorticoid receptor antagonist (MRA) has certain renal protection effect in patients with DN, and its mechanism may be related to inhibiting inflammation, reducing renal fibrosis and improving oxidative stress imbalance. This article further summarized the effects of MRA on DN, in order to provide some reference for clinical diagnosis and treatment.

  • Topic
  • Yuanying XU , Xinghua CAI , Huihui ZHANG , Wenwen KONG , Wenjun SHA , Tao LEI
    doi: 10.13683/j.wph.2023.09.002

    The pathogenesis of diabetic nephropathy (DN) is complex, involving metabolism, hemodynamics and inflammation. At present, the main treatment drugs for DN are renin-angiotensin system inhibitors, but not all patients can obtain satisfactory results. Glucagon-like peptide-1 receptor (GLP-1R), as a potential target for the treatment of DN, has great benefits in regulating blood glucose homeostasis and cardiovascular protection, and has a potential role in reducing the risk of renal adverse outcomes related to DN. This article reviewed the mechanism of GLP-1R as a therapeutic target for DN in alleviating disease progression, and discusses the efficacy of related preparations in clinical application.

  • Topic
  • Jingting WANG , Qinyi YIN , Hao LU
    doi: 10.13683/j.wph.2023.09.003

    Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes mellitus and the main cause of end-stage renal disease. In recent years, traditional Chinese medicine has certain advantages in reducing proteinuria, protecting renal function and delaying the progression of DN. Clinically, DN is usually treated by syndrome differentiation and type treatment, traditional prescription and Chinese patent medicine, and the effect is remarkable. This article reviewed the recent progress of randomized controlled studies in the treatment of DN with traditional Chinese medicine in accordance with the requirements of evidence-based medicine, in order to provide some reference for its prevention and treatment.

  • Topic
  • Yilei CONG , Tengfei WU , Jie MIN , Yiyun ZHU , Shisi XIA , Yue YUAN , Xinyu YANG , Hua YANG
    doi: 10.13683/j.wph.2023.09.004

    Sodium-glucose linked transporter-2 inhibitor (SGLT-2i) is a commonly used oral hypoglycemic agent in clinical practice, which reduces blood glucose by inhibiting renal tubule glucose reabsorption and increasing urinary glucose excretion, while increasing urinary sodium excretion. It plays the role of reducing blood pressure and reducing body mass, and treats diabetic nephropathy (DN) in multiple ways. This article briefly summarized the role, mechanism and clinical efficacy of SGLT-2i in the occurrence and development of DN, aiming to provide some reference for clinical practice.

  • Article
  • Lu LYU , Chunxia ZHAI , Jingjing LI
    doi: 10.13683/j.wph.2023.09.005
    Objective

    To investigate the effects of kaempferol on ferroptosis in trophoblast cells induced by high glucose by regulating nuclear factor erythroid-2 related factor (Nrf)2/solute carrier family 7 member (SLC7A)11/glutathione peroxidase (GPX)4 signaling pathway.

    Methods

    Human chorionic trophoblast cells HTR-8/SVneo were cultured in vitro and divided into control group, model group (25 mmol/L glucose), kaempferol group, ML385 (Nrf2 inhibitor) group, kaempferol+ML385 group. Cell counting kit-8 was used to detect the cell survival rate. Flow cytometry was used to detect the apoptosis rate. Enzyme linked immunosorbent assay was used to detect the levels of lactate dehydrogenase (LDH), interleukin (IL)-6, IL-18, and tumor necrosis factor (TNF)-α. The biochemical method was used to detect the antioxidant factors superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), malondialdehyde (MDA), iron content and relative levels of reactive oxygen species (ROS). Western blot was used to detect the expression of Nrf2/SLC7A11/GPX4 signal-related proteins in HTR-8/SVneo cells of each group.

    Results

    Kaempferol can increase the cell survival rate, SOD, CAT, GSH levels and the protein expressions of Nrf2, SLC7A11 and GPX4, reduce LDH release, apoptosis rate, IL-6, IL-18, TNF-α, MDA, ROS levels and iron content, and inhibit the ferroptosis of trophoblast cells induced by high glucose. ML385 can enhance the ferroptosis of trophoblast cells induced by high glucose, and weaken the inhibitory effect of kaempferol on the ferroptosis of trophoblast cells induced by high glucose.

    Conclusion

    Kaempferol may inhibit high glucose-induced inflammation and lipid peroxidation in trophoblast cells by activating Nrf2/SLC7A11/GPX4 signaling pathway, and alleviate ferroptosis.

  • Article
  • Xiaocong JIANG , Xiuhua PAN , Wenjuan CAI , Chi ZHANG , Yuhong LAN
    doi: 10.13683/j.wph.2023.09.006
    Objective

    To investigate the effects of honokiol on vasculogenic mimicry (VM) and epithelial-mesenchymal transition (EMT) of cervical cancer cells by regulating epidermal growth factor receptor (EGFR) signaling pathway.

    Methods

    HeLa cervical cancer cells were divided into control group, honokiol low-dose, medium-dose and high-dose groups, honokiol+NSC228155 group, and cetuximab group. Transwell chambers were used to detect cell invasion. Scratch assay was applied to detect cell migration. Periodic acid-Schiff was used to observe the formation of VM in HeLa cells. Western blot and quantitative real time fluorescent polymerase chain reaction were applied to detect the protein and gene expression in cells.

    Results

    Compared with the control group, the number of HeLa cell invasion, scratch healing rate, number of ring structures, the ratio of phosphorylated EGFR (p-EGFR)/EGFR, the expression of matrix metalloproteinase (MMP)2, MMP9, erythropoietin-producing hepatocyte receptor (Eph) A2, vascular endothelial growth factor (VEGF), neural cadherin (CDH2) and vimentin in the low, medium and high dose honokiol groups were decreased, and the expression of epithelial cadherin (CDH1) was increased (P<0.01). Compared with the high-dose honokiol group, the number of invasion, scratch healing rate, number of ring structures, the ratio of p-EGFR/EGFR, the expression of MMP2, MMP9, EphA2, VEGF, CDH2 and Vimentin in the honokiol+NSC228155 group were increased, and the expression of CDH1 was decreased (P<0.01).

    Conclusion

    Honokiol may inhibit VM formation and EMT of cervical cancer cells by inhibiting the EGFR signaling pathway.

  • Article
  • Xiaoxiao SHI , Xiang DONG , Ruohui YU , Junjun SU , Dongdong QI , Yang BAI , Meng DONG
    doi: 10.13683/j.wph.2023.09.007
    Objective

    To investigate the effects of long non-coding (lnc) RNA small nucleolar RNA host gene 16 (SNHG16) on proliferation, apoptosis and oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) cell and its possible mechanism.

    Methods

    Real time fluorescent quantitative polymerase chain reaction was used to detect the expression of lncRNA SNHG16 and microRNA (miR)-205-5p in HepG2, HL7702 cells and HCC drug resistant cells (HepG2/OXA). Methyl thiazolyl tetrazolium and flow cytometry were used to detect cell proliferation and apoptosis. The online database was used to predict the target gene of lncRNA SNHG16, and the double luciferase reporting experiment was used to verify the binding relationship between the two. Western blot was used to detect the expression of multidrug resistance protein (MRP)1, cyclin D1, cleaved caspase-3 and Akt/mammalian target of rapamycin (mTOR) signaling pathway related proteins.

    Results

    The expression of lncRNA SNHG16 in HepG2/OXA cells was significantly increased compared with HepG2 and HL7702 cells (P<0.05). The inhibitory effect of OXA on the proliferation activity of HepG2/OXA cells was enhanced with increasing concentration. Compared with the control group, the drug resistance sensitivity, cell viability, the protein expression of MRP1, cyclinD1, phosphorylated (p) mTOR, and p-Akt in HepG2/OXA cells in si-SNHG16 group were decreased, but cleaved caspase-3 protein expression and apoptosis rate were significantly increased (P<0.05). MiR-205-5p was a target gene of lncRNA SNHG16. Down-regulation of miR-205-5p reversed the inhibition/promotion of SNHG16 on drug resistance sensitivity, proliferation, apoptosis and signaling pathway of HepG2/OXA cells.

    Conclusion

    LncRNA SNHG16 activates Akt/mTOR pathway by targeting miR-205-5p, inhibits cell proliferation, induces cell apoptosis, and promotes OXA resistance in HCC cells.

  • Article
  • Tao SHEN , Lihua WANG , Xiaotian XIE
    doi: 10.13683/j.wph.2023.09.008
    Objective

    To review and analyze the effects of voriconazole in the treatment of invasive fungal infection (IFI) secondary to blood tumors in children.

    Methods

    Through the network resource sharing information platform, systematic analysis method was used to search the mainstream medical database in China, and the case reports on voriconazole treatment of IFI in children with blood tumors were collected. The overall efficacy, safety degree and related clinical information were statistically summarized.

    Results

    A total of 21 clinical data, including 558 cases, were collected and could be analyzed. The results were as follows. The total effective rate of voriconazole in the treatment of IFI in children with blood tumors was 81.36%. Voriconazole was suitable for both infants and older children. The efficacy of voriconazole was better than that of amphotericin, but there was no difference between voriconazole and echinocin. The efficacy of domestic and imported preparations of voriconazole was similar (80.88% vs 82.75%, P=0.683). Voriconazole has high safety. The common adverse reactions of voriconazole were mild gastrointestinal reactions, liver injury and hypokalemia.

    Conclusion

    Voriconazole is the preferred antifungal drug for the treatment of IFI in children with hematologic tumors. It is necessary to constantly summarize and improve the quality of diagnosis and treatment of IFI based on strict implementation of relevant diagnosis and treatment guidelines, and pay attention to the development trend of potential drug resistance..

  • Article
  • Lihua HU , Xiaohui LIU , Xin LIU , Yuncui YU , Huijie HUANG , Li XIANG , Xiaoling WANG
    doi: 10.13683/j.wph.2023.09.009
    Objective

    To construct and evaluate the reliability of outpatient service system of medication therapy management (MTM) for children with bronchial asthma (BA) based on Delphi method.

    Methods

    According to the literature and clinical practice, Delphi method was used to consult the experts to determine the specific contents of the outpatient service system of MTM for children's BA.

    Results

    A total of 2 rounds of expert consultation were conducted, and 25 questionnaires were sent out in each round, and the questionnaire recovery rate was 100%. Finally, an outpatient service system of MTM for children's BA with 3 first-level items, 12 second-level items and 55 third-level items was formed. The expert authority coefficient of the two rounds of correspondence was 0.88, 0.89, and the expert coordination coefficient was 0.206 - 0.272, respectively. The expert authority degree was high, the expert opinions were consistent, and the results were reliable.

    Conclusion

    The contents of the outpatient service system for MTM of BA in children established by Delphi method are scientific and reliable.

  • Article
  • Ke HU , Guoxiang TAN , Qiwu XU
    doi: 10.13683/j.wph.2023.09.010
    Objective

    To compare the clinical efficacy of pentoxifylline and Xuesaitong in the treatment of acute cerebral infarction (ACI).

    Methods

    A total of 160 patients with ACI hospitalized in department of neurology, Tongling municipal hospital from July 2020 to July 2022 were selected as the research objects. They were divided into observation group and control group, with 80 cases in each group. The observation group was given pentoxifylline on the basis of conventional treatment, and the control group was given Xuesaitong on the basis of conventional treatment. National Institute of Health stroke scale (NIHSS) and mini-mental state examination (MMSE) were used to evaluate the degree of neurological impairment and cognitive function. The clinical efficacy, changes of plasma fibrinogen (FIB) and hypersensitivity C-reaction protein (hs-CRP) levels before and after treatment were compared between the two groups, and the adverse reactions were observed.

    Results

    The effective rate of observation group was higher than that of control group (86.25% vs 71.25%, P<0.05). After treatment, the MMSE scores of both groups increased compared to before treatment (P<0.05), while the NIHSS score and FIB level decreased compared to before treatment (P<0.05), and the improvements of the observation group were better than those of the control group (P<0.05). The incidence of progressive cerebral infarction in the observation group was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Pentoxifylline has better clinical efficacy than Xuesaitong in the treatment of ACI, which can effectively improve neurological deficits symptoms and cognitive function, and reduce the levels of plasma FIB and hs-CRP, and it is rather safe.

  • Article
  • Qiuju LI , Bin LIU , Yunyun ZHENG , Wenbo ZHANG , Fang YAN , Yuhui WANG
    doi: 10.13683/j.wph.2023.09.011
    Objective

    To explore the relationship between blood homocysteine (Hcy) level and cognitive impairment in patients with acute ischemic stroke (AIS), and the effects of triple lowering Hcy by vitamin B12, folic acid and vitamin B6 on cognitive function.

    Methods

    A total of 74 initial AIS patients admitted to the department of neurology of Shanghai Punan hospital of Pudong new district were continuously enrolled. The patients were divided into hyperhomocysteinemia (HHcy) group (n=41, Hcy≥10 μmol/L) and low homocysteine (LHcy) group (n=33, Hcy<10 μmol/L) according to the blood Hcy level at the time of enrollment. Baseline cognitive function was assessed 7 days after enrollment. The patients in HHcy group were treated by oral 1 mg of mecobalamin, 5 mg of folic acid and 20 mg of vitamin B6 every day, and cognitive evaluation and blood Hcy levels were measured at 3, 6 and 12 months respectively after treatment. The differences in baseline vascular risk factors, cognitive score at baseline and changes of cognitive scores at follow-up were compared between the two groups.

    Results

    At baseline, the average blood Hcy levels in HHcy group and the LHcy group were (18.86±12.44) and (8.42±1.54) μmol/L, respectively. There were more male patients and smokers in the HHcy group, and the levels of blood folic acid and vitamin B12 were significantly lower than those of the LHcy group (P<0.01). The Montreal cognitive assessment scale (MoCA) score in HHcy group was significantly lower than that of the LHcy group (P<0.05). After 12 months of triple therapy of mecobalamin, folic acid, and vitamin B6, the blood Hcy level in the HHcy group were significantly reduced, the MoCA score was increased (P<0.01).

    Conclusion

    HHcy is a close but interventionable risk factor for post-stroke cognitive impairment. Triple Hcy lowering treatment can significantly reduce the Hcy level and may help to delay the cognitive decline in AIS patients.

  • Article
  • Jing LI , Haifeng NAN
    doi: 10.13683/j.wph.2023.09.012
    Objective

    To explore the effects of Relinqing granules combined with cefodizime sodium in the treatment of male gonorrhea.

    Methods

    A total of 80 male patients with gonorrhea from January 2018 to December 2020 were selected, grouped according to random number table method. There were 40 cases in the control group (treated with cefodizime sodium) and 40 cases in the observation group (treated with cefodizime sodium combined with Relinqing granules), and compare clinical efficacy between the two groups.

    Results

    The total effective rate of the observation group was higher than that of the control group (100.00% vs 80.00%), and the difference was statistically significant (P<0.05). The positive rates of gonococci in the observation group on D3 and D8 were 37.35% and 2.50%, respectively, lower than the 62.50% and 22.50% in the control group. After treatment, the levels of interleukin (IL)-10, IL-6 and tumor necrosis factor-α in both groups were decreased, and the levels of observation group were lower than those of the control group (P<0.05). After treatment, the quality of life scores of both groups of patients were improved, and these indicators of observation group were higher than those of the control group (P<0.05). During the treatment period, there was no statistically significant difference in adverse reactions between the observation group (2.50%) and the control group (7.50%). The incidence of gonorrhea complications in the observation group (2.5%) was lower than that in the control group (25.00%)(P<0.05).

    Conclusion

    After the treatment of male gonorrhea patients with Relinqing granules, the positive rate of gonococci was significantly reduced, the serum inflammatory factors and quality of life of the patients were also significantly improved, and the treatment was safe. It had an effective prevention effect on the occurrence of complications, with significant clinical application value.

  • Article
  • Danhua ZHAO , Hailong XU , Minqiang LI , Hong LIU , Haifang MA , Ansheng CAI
    doi: 10.13683/j.wph.2023.09.013
    Objective

    To explore the therapeutic effects of diltiazem hydrochloride combined with Xinbao pills on coronary microvascular disease (CMVD).

    Methods

    A total of 198 patients with CMVD angina treated in the affiliated hospital of Hebei engineering university from August 2020 to August 2022 were selected as the study objects. They were divided into control group (treated with diltiazem hydrochloride) and intervention group (treated with diltiazem hydrochloride and Xinbao pills) by random number table method, with 99 cases in each group. The total effective rate was compared between the two groups. The blood rheological indexes, vascular endothelial function indexes, serum endothelial cell specific molecule (ESM)1, visceral adipose tissue-derived serine protease inhibitor (Vaspin) and the occurrence of adverse reactions were compared before and after treatment.

    Results

    The total effective rate of intervention group was higher than that of control group. After treatment, the levels of whole blood high shear viscosity, whole blood low shear viscosity, thrombomodulin, von Willebrand factor, endothelin-1 and ESM1 in the intervention group were lower than those in the control group. The levels of fibrinogen, hematocrit and Vaspin were higher than those in the control group, and the differences were statistically significant (P<0.05). No drug-related adverse reactions were observed in the two groups during treatment.

    Conclusion

    Diltiazem hydrochloride combined with Xinbao pills can improve the efficacy of CMVD patients, improve the hemodynamic indexes of patients, protect vascular endothelial function, regulate the expression levels of Vaspin and ESM1, and have good safety.

  • Article
  • Shichong ZHOU , Yijun ZHUANG , Hongming ZENG , Deli ZENG , Wenchao XU
    doi: 10.13683/j.wph.2023.09.014
    Objective

    To investigate the effects of acetyl-L-carnitine and mecobalamine on pain, nerve conduction velocity in patients with diabetic peripheral neuropathy (DPN).

    Methods

    A total of 80 DPN patients admitted to our hospital from January 2021 to November 2022 were selected and divided into observation group (conventional treatment+acetyl-L-carnitine) and control group (conventional treatment+mecobalamine) according to random number table method, 40 cases in each group, all of which were treated for 3 months. Pain relief, visual analogue scale (VAS) score, blood glucose, sensory nerve conduction velocity (SNCV) of median nerve and common peroneal nerve, motor nerve conduction velocity (MNCV) changes and adverse reactions were compared between the two groups.

    Results

    The total effective rate of pain relief in observation group was higher than that in control group (P<0.05). VAS score of observation group was lower than that of control group (P<0.05). There was no significant difference in SNCV and MNCV between the median nerve and common peroneal nerve between the two groups (P>0.05).

    Conclusion

    Acetyl-L-carnitine and mecobalamine have similar effects in improving nerve conduction velocity in DPN patients, and acetyl-L-carnitine has better effects in relieving pain, and has high clinical application value.

  • Article
  • Jiahao HU , Yuhan LIU , Xingming PAN , Chunlin JIN , Fen LI
    doi: 10.13683/j.wph.2023.09.015
    Objective

    To evaluate the cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis (IPF).

    Methods

    From the perspective of Chinese healthcare system, a Markov model was constructed to evaluate the cost-effectiveness of nintedanib esylate compared with pirfenidone in the treatment of IPF patients. The model cycle was one month using a lifetime horizon. The discount rate of both cost and effectiveness was 5%. One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were used to verify the robustness of the base case results.

    Results

    The results of the base case showed that compared with generic pirfenidone, nintedanib esylate had lower costs and higher quality-adjusted life years output in the treatment of IPF patients, which had absolute advantages and was a more economical program. The conclusion was verified in one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis.

    Conclusion

    Nintedanib esylate is a cost-effective alternative compared with generic pirfenidone in Chinese patients with IPF.

  • Review
  • Yaan ZHANG , Yukun WANG , Wei SHEN
    doi: 10.13683/j.wph.2023.09.016

    Zuranolone is a new neuroactive steroid drug, which acts on the positive allosteric modulation of γ-aminobutyric acid type A receptor, and is expected to become a new treatment for depression. The results of phase Ⅲ clinical trials showed that zuranolone could rapidly improve depressive symptoms with the treatment of oral administration once a day for 2 weeks, and the overall tolerance was good. This article reviewed the pharmacological action, pharmacokinetics, safety and clinical research progress in zuranolone.

  • Pharmacy administration
  • Lin ZHU , Jiahao HU , Yuhan LIU , Fen LI , Chunlin JIN
    doi: 10.13683/j.wph.2023.09.017

    High-value orphan drugs for rare diseases can fill the clinical therapeutic gaps and significantly improve symptoms and patients' quality of life compared with standard treatment regimens. However, due to uncertainties in the number of patients, real-world efficacy and safety performance of drug, and fund budget impact and other factors, the decision-making risk of the medical insurance department is extremely uncertain. The high price also leads to the increasing difficulty of medical insurance access. Due to the particularity of rare diseases, there are certain limitations in drug list adjustments using the same selection and evaluation principle of conventional drugs and following the track of "strict access, loose extension" for high-value orphan drugs. According to the international experience, the medical insurance access of rare disease drugs needs a differentiated evaluation system. This article explored the dilemma of medical insurance access for high-value orphan drugs and analyzes the causes. Drawing on international experiences and combining with domestic medical insurance access practice, we put forward some ideas to improve the medical insurance access for high-value orphan drugs in China, in order to provide references for relevant department to make adjustments on the medical security for rare diseases and innovate the selection and evaluation mechanism, and further improve the accessibility of high-value orphan drugs for patients with rare diseases.

  • Pharmacy administration
  • Jiajie XU , Dawei LYU , Chunlin JIN
    doi: 10.13683/j.wph.2023.09.018

    This paper reviewed the system design and reform experience of health insurance and payment system in Chinese Taiwan from the aspects of the health insurance system and health insurance payment system, also provided references for the reform of medical and health system in Chinese mainland, including building a multi-channel financing system, continuously promoting the reform of medical insurance payment methods, introducing third-party institutions to formulate budget and payment standards, and strengthening medical service supervision and construction of information standardization.

  • Pharmacy administration
  • Jiaqi LIANG , Caixia LI , Fanyu LIN , Yunxin JING , Pengcheng LIU
    doi: 10.13683/j.wph.2023.09.019
    Objective

    To explore the way of carrying out the risk communication method of "patient safety medication guides" in China.

    Methods

    We reviewed the guidelines and regulations on "patient safety medication guides" issued by the drug regulatory authorities in typical countries, the United States and Japan, and the differences in their production, format content and other aspects were analyzed.

    Result

    Although both the United States and Japan implement the "patient safety medication guides" work, there are different regulatory requirements in various aspects. In addition, Japan does not have specific requirements for the format of patients safe medication, nor does it elaborate on the specific distribution requirements.

    Conclusion

    China could appropriately learn from the advanced experience of the United States and Japan, carry out the work of "patient safety medication guides", issue relevant guidelines as soon as possible, and specify the specific production requirements of "patient safety medication guides" in detail.

  • Pharmacy administration
  • Misu XIAO , Wenqing ZHU , Yuanfeng NI , Qianyue YAO , Hongyi HU
    doi: 10.13683/j.wph.2023.09.020
News